Skip to main content
| News

Resistell seeking to further develop test to combat antibiotic resistance

26.04.2022

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being funded by an independent grant from Pfizer. In so doing, the company from Muttenz in the canton of Basel-Landschaft is seeking to facilitate the continued use of antibiotics in a targeted, precise manner.

The biotech firm Resistell from Muttenz in the canton of Basel-Landschaft has received a grant from the Zurich-based pharmaceutical company Pfizer AG for a research project. For this, the spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL) is seeking to assess the applicability of its antibiotic susceptibility test (AST) against a novel antibiotic, further details of which can be found in a press release. The study aims to provide a proof of concept for the AST developed by Resistell.

According to information from the company itself, a positive outcome in connection with this research project could help to generate a paradigm shift in the management of infectious diseases and open the door to informed, diagnostics-based treatment decisions. “Targeted and precise use of antibiotics is ever more important in the light of constantly increasing multidrug-resistant infections. Resistell’s rapid phenotypic AST enables adequate antibiotic therapy for critically ill patients, which not only saves lives but also extends the lifetime of novel antibiotics that are so scarce nowadays”, explains Danuta Cichocka, CEO of Resistell, in the press release.

Reduction of the test duration

Founded in 2018, Resistell claims to have developed the world’s fastest antibiotic susceptibility test. It is based on the analysis of nano-scale vibrations of living cells. The AST developed by Resistell reduces the duration of a test from what previously took many hours or even days to just a couple of hours. It is hoped that it could help to solve one of the greatest challenges facing the healthcare sector, namely the increasing resistance of pathogens to antibiotics.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest

Official opening of the competence center uptownBasel

uptownBasel celebrated its official opening. Technology companies such as Bouygues and Vinci Energies are already occupying the first building of...

Read More
Basel Area Business & Innovation, Innovation, Life Sciences / biotech, Medtech, Switzerland Innovation Park

Eight startups from Basel Area feature in TOP 100 Swiss Startups

Among the most promising startups in Switzerland eight companies from Basel Area's startup ecosystem have been named. They are some...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Roche opens tallest building in Switzerland

Roche has inaugurated a new office building with 3,200 positions in Basel. Standing 205 meters high, Building 2 is the...

Read More
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

DayOne Tech supports three medtech startups

DayOne, the healthcare innovation initiative from Basel Area Business & Innovation, has started its medtech accelerator in the canton of...

Read More
Basel Area achieves milestone with settling of LifeMine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel Area achieves milestone with settling of LifeMine

Life sciences company LifeMine Therapeutics from the USA has established its European headquarters in the Basel Area. With this, Basel...

Read More
1 2 3 57

Do you have a question? We'd like to hear from you.